Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Mark Iwicki
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:foundedYear |
2009
|
| gptkbp:founder |
gptkb:Robert_Langer
Justin Hanes Kimberly D. Brazzell Mark Iwicki |
| gptkbp:headquartersLocation |
gptkb:Watertown,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Kala Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:product |
EYSUVIS
INVELTYS |
| gptkbp:specializesIn |
ophthalmology
ocular therapies |
| gptkbp:status |
gptkb:public_company
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
KALA
|
| gptkbp:technology |
AMPPLIFY drug delivery platform
|
| gptkbp:website |
https://www.kalarx.com/
|
| gptkbp:bfsParent |
gptkb:Andrey_Zarur
|
| gptkbp:bfsLayer |
7
|